FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319061775> ?p ?o ?g. }

• W4319061775 endingPage "153303382211459" @default.
• W4319061775 startingPage "153303382211459" @default.
• W4319061775 abstract "Worldwide, the incidence rate of breast cancer is the highest in women. Approximately 2.3 million people were newly diagnosed and 0.685 million were dead of breast cancer in 2020, which continues to grow. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with a higher risk of recurrence and metastasis, but disappointly, there are no effective and specific therapies clinically, especially for patients presenting with metastatic diseases. Therefore, it is urgent to develop a new type of cancer therapy for survival improvisation and adverse effects alleviation of breast cancers. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed, photochemistry-based cancer therapy. It was drive by an antibody-photoabsorber conjugate (APC) which is triggered by near-infrared light. The key part of APC is a cancer-targeting monoclonal antibody (mAb) that can bind to receptors or antigens on the surface of tumor cells. Because of this targeted conjugate accumulation, subsequent deployment of focal NIR-light results in functional damage on the targeted cell membranes without harming the immediately adjacent receptor-negative cells and evokes a kind of photochemical, speedy, and highly specific immunogenic cell death (ICD) of cancer cells with corresponding antigens. Subsequently, immature dendritic cells adjacent to dying cancer cells will become mature, further inducing a host-oriented anti-cancer immune response, complicatedly and comprehensively. Currently, NIR-PIT has progressed into phase 3 clinical trial for recurrent head and neck cancer. And preclinical studies have illustrated strong therapeutic efficacy of NIR-PIT targeting various molecular receptors overexpressed in breast cancer cells, including EGFR, HER2, CD44c, CD206, ICAM-1 and FAP-α. Thereby, NIR-PIT is in early trials, but appears to be a promising breast cancer therapy and moving into the future. Here, we present the specific advantages and discuss the most recent preclinical studies against several transmembrane proteins of NIR-PIT in breast cancers." @default.
• W4319061775 created "2023-02-04" @default.
• W4319061775 creator A5043849638 @default.
• W4319061775 creator A5046059755 @default.
• W4319061775 creator A5054899321 @default.
• W4319061775 creator A5064842058 @default.
• W4319061775 creator A5065824436 @default.
• W4319061775 creator A5069382421 @default.
• W4319061775 creator A5075122118 @default.
• W4319061775 date "2023-01-01" @default.
• W4319061775 modified "2023-09-27" @default.
• W4319061775 title "Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers" @default.
• W4319061775 cites W1859923649 @default.
• W4319061775 cites W1895455527 @default.
• W4319061775 cites W1953562363 @default.
• W4319061775 cites W1968020290 @default.
• W4319061775 cites W1983692618 @default.
• W4319061775 cites W1999082469 @default.
• W4319061775 cites W2008999855 @default.
• W4319061775 cites W2044702943 @default.
• W4319061775 cites W2050753051 @default.
• W4319061775 cites W2059892673 @default.
• W4319061775 cites W2070313422 @default.
• W4319061775 cites W2095782040 @default.
• W4319061775 cites W2105241081 @default.
• W4319061775 cites W2108760763 @default.
• W4319061775 cites W2115974802 @default.
• W4319061775 cites W2116118767 @default.
• W4319061775 cites W2127778337 @default.
• W4319061775 cites W2132893003 @default.
• W4319061775 cites W2159803625 @default.
• W4319061775 cites W2161256051 @default.
• W4319061775 cites W2169599361 @default.
• W4319061775 cites W2170602872 @default.
• W4319061775 cites W2177405394 @default.
• W4319061775 cites W2235739319 @default.
• W4319061775 cites W2264956482 @default.
• W4319061775 cites W2272984102 @default.
• W4319061775 cites W2431862749 @default.
• W4319061775 cites W2470767900 @default.
• W4319061775 cites W2474034723 @default.
• W4319061775 cites W2513056697 @default.
• W4319061775 cites W2565382901 @default.
• W4319061775 cites W2606494428 @default.
• W4319061775 cites W2621644013 @default.
• W4319061775 cites W2744974851 @default.
• W4319061775 cites W2772703365 @default.
• W4319061775 cites W2788904214 @default.
• W4319061775 cites W2793882441 @default.
• W4319061775 cites W2800463206 @default.
• W4319061775 cites W2806713886 @default.
• W4319061775 cites W2900131693 @default.
• W4319061775 cites W2913388824 @default.
• W4319061775 cites W2922883130 @default.
• W4319061775 cites W2964086043 @default.
• W4319061775 cites W2990253615 @default.
• W4319061775 cites W3035007653 @default.
• W4319061775 cites W3088122442 @default.
• W4319061775 cites W3089769799 @default.
• W4319061775 cites W3090606514 @default.
• W4319061775 cites W3131048422 @default.
• W4319061775 cites W3152186591 @default.
• W4319061775 cites W3177228147 @default.
• W4319061775 cites W3203960170 @default.
• W4319061775 cites W3213671969 @default.
• W4319061775 cites W4283166925 @default.
• W4319061775 cites W4297459904 @default.
• W4319061775 cites W592456630 @default.
• W4319061775 doi "https://doi.org/10.1177/15330338221145992" @default.
• W4319061775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36734039" @default.
• W4319061775 hasPublicationYear "2023" @default.
• W4319061775 type Work @default.
• W4319061775 citedByCount "1" @default.
• W4319061775 countsByYear W43190617752023 @default.
• W4319061775 crossrefType "journal-article" @default.
• W4319061775 hasAuthorship W4319061775A5043849638 @default.
• W4319061775 hasAuthorship W4319061775A5046059755 @default.
• W4319061775 hasAuthorship W4319061775A5054899321 @default.
• W4319061775 hasAuthorship W4319061775A5064842058 @default.
• W4319061775 hasAuthorship W4319061775A5065824436 @default.
• W4319061775 hasAuthorship W4319061775A5069382421 @default.
• W4319061775 hasAuthorship W4319061775A5075122118 @default.
• W4319061775 hasBestOaLocation W43190617752 @default.
• W4319061775 hasConcept C121608353 @default.
• W4319061775 hasConcept C126322002 @default.
• W4319061775 hasConcept C143998085 @default.
• W4319061775 hasConcept C147483822 @default.
• W4319061775 hasConcept C159654299 @default.
• W4319061775 hasConcept C203014093 @default.
• W4319061775 hasConcept C2777701055 @default.
• W4319061775 hasConcept C2777877232 @default.
• W4319061775 hasConcept C2779013556 @default.
• W4319061775 hasConcept C2780110267 @default.
• W4319061775 hasConcept C2781230642 @default.
• W4319061775 hasConcept C502942594 @default.
• W4319061775 hasConcept C530470458 @default.
• W4319061775 hasConcept C71924100 @default.
• W4319061775 hasConcept C82210918 @default.

• next